🇺🇸 FDA
Pipeline program

[90Y]Y-PentixaTher, LysaKare 25 g/25 g solution for infusion, [68Ga]Ga-PentixaFor

PTT101

Phase 2 small_molecule active

Quick answer

[90Y]Y-PentixaTher, LysaKare 25 g/25 g solution for infusion, [68Ga]Ga-PentixaFor for Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary is a Phase 2 program (small_molecule) at Pharm Research Associates (UK) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharm Research Associates (UK) Limited
Indication
Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials